<DOC>
	<DOCNO>NCT01853358</DOCNO>
	<brief_summary>The goal study determine clinical biological safety infuse immuno-selected NK ( Natural Killer ) CD3-/CD56+ cell , early allogeneic transplantation colony stimulate factor ( G-CSF ) mobilize peripheral blood stem cell Reduced Intensity Conditioning ( RIC ) , potential substitute usual `` Donor Lymphocyte Infusion '' ( DLI ) , contain whole range immune effector . The trial include several progressive step : dose escalation level compatible cost-effectiveness potential device clinical situation recombinant interleukin-2 ( r-IL2 ) activation select NK cell vitro prior re-infusion .</brief_summary>
	<brief_title>Phase I Infusion Selected Donor NK Cells After Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>In mid 90 's , show donor lymphocyte infusion ( DLI ) , give Chronic Myelocytic Leukemia ( CML ) relapse conventional allogeneic stem cell transplantation ( SCT ) , result high incidence durable cytogenetic molecular remission . However , regular document effect occurrence secondary aplasia and/or graft-versus-host disease ( GVHD ) include post RIC situation . These effect relate high content cytotoxic T cell DLI . Attempts deplete CD8+ T-cells DLI conduct promising result totally satisfactory . More recently infusion r-IL2 ex-vivo activate autologous allogeneic NK-selected cell study safety establish patient present various malignancy . Indeed , NK thoroughly characterize term genotype , phenotype function . Although handful clinical-grade reagent device exist give access human NK cell compartment , immuno-selection device exists allow selection NK cell various type hematopoietic cell collection view clinical application : process produce CD3-/CD56+ cell two step use previous experience .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Patient treat allogeneic stem cell transplantation Presenting hematological malignancy intermediate , high high risk index accord disease risk index develop Dana Farber Cancer Institute Donor : HLA match relate unrelated ( 10/10 ) donor Graft : Peripheral stem cell transplant Reduced Intensity Conditioning use current transplant program : Fludarabine , IV Busulfan Thymoglobuline 2 . Age 18 70 3 . Eastern Cooperative Oncology Group ( ECOG ) 01 Karnofsky index ≥ 70 % 4 . Survival expectation &gt; 6 month 5 . Affiliation social security 6 . Signed informed consent Donor Patient 1 . Active grade &gt; = 2 acute GVHD corticotherapy ≥ 0.5 mg/kg/day time NK cell infusion 2 . Active infection 3 . Psychiatric disorder occur transplant 4 . Pregnant breastfeed woman without contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hematological malignancy</keyword>
	<keyword>stem cell transplantation</keyword>
</DOC>